{"id":476710,"date":"2021-04-15T07:33:19","date_gmt":"2021-04-15T11:33:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\/"},"modified":"2021-04-15T07:33:19","modified_gmt":"2021-04-15T11:33:19","slug":"kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\/","title":{"rendered":"Kaleido Biosciences to Participate in Jefferies Microbiome-Based Therapeutics Summit"},"content":{"rendered":"
\n

LEXINGTON, Ma., April 15, 2021 (GLOBE NEWSWIRE) — Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that CEO Dan Menichella will participate in an analyst-led fireside chat on Thursday, April 22 at the Jefferies Microbiome-Based Therapeutics Summit.<\/p>\n

The webcast of the fireside chat will be made available that morning as of 8am EDT on the Investors & Media section of Kaleido\u2019s website at\u00a0https:\/\/investors.kaleido.com\/events-presentations<\/a>. An archived replay will be available for 90 days following the event.<\/p>\n

About Kaleido Biosciences<\/strong>
Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health. The Company has built a proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT\u2122). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the gut\u2019s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. To learn more, visit\u00a0https:\/\/kaleido.com\/<\/a>.<\/p>\n

\n Contacts:<\/strong>
\n
Kaleido Biosciences
William Duke, Jr.
Chief Financial Officer
617-890-5772
william.duke@kaleido.com<\/a>\u00a0<\/p>\n

\n Investors<\/strong>
\n
Mike Biega
Solebury Trout
617-221-9660
mbiega@soleburytrout.com<\/a>\u00a0<\/p>\n

\n Media<\/strong>
\n
Amy Bonanno
Solebury Trout
914-450-0349
abonanno@soleburytrout.com<\/a><\/p>\n

SOURCE: Kaleido Biosciences<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

LEXINGTON, Ma., April 15, 2021 (GLOBE NEWSWIRE) — Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that CEO Dan Menichella will participate in an analyst-led fireside chat on Thursday, April 22 at the Jefferies Microbiome-Based Therapeutics Summit. The webcast of the fireside chat will be made available that morning as of 8am EDT on the Investors & Media section of Kaleido\u2019s website at\u00a0https:\/\/investors.kaleido.com\/events-presentations. An archived replay will be available for 90 days following the event. About Kaleido BiosciencesKaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health. The … <\/p>\n

Continue reading “Kaleido Biosciences to Participate in Jefferies Microbiome-Based Therapeutics Summit”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-476710","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nKaleido Biosciences to Participate in Jefferies Microbiome-Based Therapeutics Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kaleido Biosciences to Participate in Jefferies Microbiome-Based Therapeutics Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LEXINGTON, Ma., April 15, 2021 (GLOBE NEWSWIRE) — Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that CEO Dan Menichella will participate in an analyst-led fireside chat on Thursday, April 22 at the Jefferies Microbiome-Based Therapeutics Summit. The webcast of the fireside chat will be made available that morning as of 8am EDT on the Investors & Media section of Kaleido\u2019s website at\u00a0https:\/\/investors.kaleido.com\/events-presentations. An archived replay will be available for 90 days following the event. About Kaleido BiosciencesKaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health. The … Continue reading "Kaleido Biosciences to Participate in Jefferies Microbiome-Based Therapeutics Summit"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-15T11:33:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNjIwNCM0MTE4ODk1IzIxMjQyNjc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kaleido Biosciences to Participate in Jefferies Microbiome-Based Therapeutics Summit\",\"datePublished\":\"2021-04-15T11:33:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\\\/\"},\"wordCount\":246,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNjIwNCM0MTE4ODk1IzIxMjQyNjc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\\\/\",\"name\":\"Kaleido Biosciences to Participate in Jefferies Microbiome-Based Therapeutics Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNjIwNCM0MTE4ODk1IzIxMjQyNjc=\",\"datePublished\":\"2021-04-15T11:33:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNjIwNCM0MTE4ODk1IzIxMjQyNjc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNjIwNCM0MTE4ODk1IzIxMjQyNjc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kaleido Biosciences to Participate in Jefferies Microbiome-Based Therapeutics Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kaleido Biosciences to Participate in Jefferies Microbiome-Based Therapeutics Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\/","og_locale":"en_US","og_type":"article","og_title":"Kaleido Biosciences to Participate in Jefferies Microbiome-Based Therapeutics Summit - Market Newsdesk","og_description":"LEXINGTON, Ma., April 15, 2021 (GLOBE NEWSWIRE) — Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that CEO Dan Menichella will participate in an analyst-led fireside chat on Thursday, April 22 at the Jefferies Microbiome-Based Therapeutics Summit. The webcast of the fireside chat will be made available that morning as of 8am EDT on the Investors & Media section of Kaleido\u2019s website at\u00a0https:\/\/investors.kaleido.com\/events-presentations. An archived replay will be available for 90 days following the event. About Kaleido BiosciencesKaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health. The … Continue reading \"Kaleido Biosciences to Participate in Jefferies Microbiome-Based Therapeutics Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-15T11:33:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNjIwNCM0MTE4ODk1IzIxMjQyNjc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kaleido Biosciences to Participate in Jefferies Microbiome-Based Therapeutics Summit","datePublished":"2021-04-15T11:33:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\/"},"wordCount":246,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNjIwNCM0MTE4ODk1IzIxMjQyNjc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\/","name":"Kaleido Biosciences to Participate in Jefferies Microbiome-Based Therapeutics Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNjIwNCM0MTE4ODk1IzIxMjQyNjc=","datePublished":"2021-04-15T11:33:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNjIwNCM0MTE4ODk1IzIxMjQyNjc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNjIwNCM0MTE4ODk1IzIxMjQyNjc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaleido-biosciences-to-participate-in-jefferies-microbiome-based-therapeutics-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kaleido Biosciences to Participate in Jefferies Microbiome-Based Therapeutics Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/476710","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=476710"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/476710\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=476710"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=476710"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=476710"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}